Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-β and NF-κB

Wen Chin Lee; Hong Chen Chen; Chih Ying Wang; Pei Ying Lin; Tin Tsz Ou; Chen Chang Chen; Mei Chin Wen; John Wang; Huei Jane Lee

doi:10.1271/bbb.90938

Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-β and NF-κB

Wen Chin Lee, Hong Chen Chen, Chih Ying Wang, Pei Ying Lin, Tin Tsz Ou, Chen Chang Chen, Mei Chin Wen, John Wang, Huei Jane Lee^*

^*Corresponding author for this work

Institute of Biochemistry and Molecular Biology

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Diabetic nephropathy is characterized as the progressive development of renal insufficiency in a setting of hyperglycemia. Previous studies indicate that reactive oxygen species (ROS) play an important role in high glucose-induced renal injury. Cilostazol was reported to lower the production of superoxide significantly in situ. We hypothesized that cilostazol administration in streptozotocin-induced diabetic rats exerts effects via improving oxidative stress. Male Sprague-Dawley rats were fed with cilostazol (5mg/kg or 25mg/kg) for 12 weeks after streptozotocin-induced diabetes mellitus. The results showed that cilostazol decreased reactive oxygen species activity significantly in the kidneys of diabetic rats and improved the urine albumin/creatinine ratio. Cilostazol can also improve the levels of serum cholesterol, triglyceride, and LDL-cholesterol. Additionally, diabetes-caused increased glomerular size, TGF-β, and NF-κB decreased under treatment with cilostazol in diabetic rats. Our results indicate that cilostazol has beneficial effects in early diabetic nephropathy.

Original language	English
Pages (from-to)	1355-1361
Number of pages	7
Journal	Bioscience, Biotechnology and Biochemistry
Volume	74
Issue number	7
DOIs	https://doi.org/10.1271/bbb.90938
State	Published - 2010

Keywords

Cilostazol
Diabetic nephropathy
NF-κB
Oxidative stress
TGF-β

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1271/bbb.90938

Cite this

@article{2f9f8b11c2e24d618fc9dd2bfd279ca7,

title = "Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-β and NF-κB",

abstract = "Diabetic nephropathy is characterized as the progressive development of renal insufficiency in a setting of hyperglycemia. Previous studies indicate that reactive oxygen species (ROS) play an important role in high glucose-induced renal injury. Cilostazol was reported to lower the production of superoxide significantly in situ. We hypothesized that cilostazol administration in streptozotocin-induced diabetic rats exerts effects via improving oxidative stress. Male Sprague-Dawley rats were fed with cilostazol (5mg/kg or 25mg/kg) for 12 weeks after streptozotocin-induced diabetes mellitus. The results showed that cilostazol decreased reactive oxygen species activity significantly in the kidneys of diabetic rats and improved the urine albumin/creatinine ratio. Cilostazol can also improve the levels of serum cholesterol, triglyceride, and LDL-cholesterol. Additionally, diabetes-caused increased glomerular size, TGF-β, and NF-κB decreased under treatment with cilostazol in diabetic rats. Our results indicate that cilostazol has beneficial effects in early diabetic nephropathy.",

keywords = "Cilostazol, Diabetic nephropathy, NF-κB, Oxidative stress, TGF-β",

author = "Lee, {Wen Chin} and Chen, {Hong Chen} and Wang, {Chih Ying} and Lin, {Pei Ying} and Ou, {Tin Tsz} and Chen, {Chen Chang} and Wen, {Mei Chin} and John Wang and Lee, {Huei Jane}",

note = "Funding Information: This work was supported by a Show Chwan Memorial Hospital Grant (RD 97005, RD 98002) and a Taiwan National Science Council Grant (NSC97-2321-B-040-003).",

year = "2010",

doi = "10.1271/bbb.90938",

language = "English",

volume = "74",

pages = "1355--1361",

journal = "Bioscience, Biotechnology and Biochemistry",

issn = "0916-8451",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-β and NF-κB

AU - Lee, Wen Chin

AU - Chen, Hong Chen

AU - Wang, Chih Ying

AU - Lin, Pei Ying

AU - Ou, Tin Tsz

AU - Chen, Chen Chang

AU - Wen, Mei Chin

AU - Wang, John

AU - Lee, Huei Jane

N1 - Funding Information: This work was supported by a Show Chwan Memorial Hospital Grant (RD 97005, RD 98002) and a Taiwan National Science Council Grant (NSC97-2321-B-040-003).

PY - 2010

Y1 - 2010

N2 - Diabetic nephropathy is characterized as the progressive development of renal insufficiency in a setting of hyperglycemia. Previous studies indicate that reactive oxygen species (ROS) play an important role in high glucose-induced renal injury. Cilostazol was reported to lower the production of superoxide significantly in situ. We hypothesized that cilostazol administration in streptozotocin-induced diabetic rats exerts effects via improving oxidative stress. Male Sprague-Dawley rats were fed with cilostazol (5mg/kg or 25mg/kg) for 12 weeks after streptozotocin-induced diabetes mellitus. The results showed that cilostazol decreased reactive oxygen species activity significantly in the kidneys of diabetic rats and improved the urine albumin/creatinine ratio. Cilostazol can also improve the levels of serum cholesterol, triglyceride, and LDL-cholesterol. Additionally, diabetes-caused increased glomerular size, TGF-β, and NF-κB decreased under treatment with cilostazol in diabetic rats. Our results indicate that cilostazol has beneficial effects in early diabetic nephropathy.

AB - Diabetic nephropathy is characterized as the progressive development of renal insufficiency in a setting of hyperglycemia. Previous studies indicate that reactive oxygen species (ROS) play an important role in high glucose-induced renal injury. Cilostazol was reported to lower the production of superoxide significantly in situ. We hypothesized that cilostazol administration in streptozotocin-induced diabetic rats exerts effects via improving oxidative stress. Male Sprague-Dawley rats were fed with cilostazol (5mg/kg or 25mg/kg) for 12 weeks after streptozotocin-induced diabetes mellitus. The results showed that cilostazol decreased reactive oxygen species activity significantly in the kidneys of diabetic rats and improved the urine albumin/creatinine ratio. Cilostazol can also improve the levels of serum cholesterol, triglyceride, and LDL-cholesterol. Additionally, diabetes-caused increased glomerular size, TGF-β, and NF-κB decreased under treatment with cilostazol in diabetic rats. Our results indicate that cilostazol has beneficial effects in early diabetic nephropathy.

KW - Cilostazol

KW - Diabetic nephropathy

KW - NF-κB

KW - Oxidative stress

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=77955198782&partnerID=8YFLogxK

U2 - 10.1271/bbb.90938

DO - 10.1271/bbb.90938

M3 - Article

C2 - 20622454

AN - SCOPUS:77955198782

SN - 0916-8451

VL - 74

SP - 1355

EP - 1361

JO - Bioscience, Biotechnology and Biochemistry

JF - Bioscience, Biotechnology and Biochemistry

IS - 7

ER -

Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-β and NF-κB

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this